1.64 USD
-0.02 (-1.2%)
We assign a fundamental rating of 4 out of 10 to AKBA. AKBA was compared to 530 industry peers in the Biotechnology industry. AKBA has a medium profitability rating, but doesn't score so well on its financial health evaluation. AKBA has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year AKBA has reported negative net income.
AKBA had a positive operating cash flow in the past year.
AKBA had negative earnings in each of the past 5 years.
AKBA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
AKBA's Return On Assets of -4.37% is amongst the best of the industry. AKBA outperforms 86.23% of its industry peers.
The Return On Equity of AKBA (-38.24%) is better than 71.70% of its industry peers.
The Return On Invested Capital of AKBA (6.90%) is better than 93.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -38.24% | ||
| ROIC | 6.9% |
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AKBA has a better Operating Margin (8.95%) than 90.94% of its industry peers.
AKBA has a better Gross Margin (82.52%) than 86.04% of its industry peers.
AKBA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.95% | ||
| PM (TTM) | N/A | ||
| GM | 82.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AKBA is destroying value.
Compared to 1 year ago, AKBA has more shares outstanding
Compared to 5 years ago, AKBA has more shares outstanding
AKBA has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -4.39, we must say that AKBA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of AKBA (-4.39) is worse than 60.00% of its industry peers.
AKBA has a debt to FCF ratio of 5.97. This is a neutral value as AKBA would need 5.97 years to pay back of all of its debts.
The Debt to FCF ratio of AKBA (5.97) is better than 90.94% of its industry peers.
A Debt/Equity ratio of 4.30 is on the high side and indicates that AKBA has dependencies on debt financing.
AKBA has a worse Debt to Equity ratio (4.30) than 82.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.3 | ||
| Debt/FCF | 5.97 | ||
| Altman-Z | -4.39 |
ROIC/WACC0.87
WACC7.93%
2.3 Liquidity
A Current Ratio of 1.94 indicates that AKBA should not have too much problems paying its short term obligations.
AKBA has a Current ratio of 1.94. This is in the lower half of the industry: AKBA underperforms 77.55% of its industry peers.
AKBA has a Quick Ratio of 1.80. This is a normal value and indicates that AKBA is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of AKBA (1.80) is worse than 77.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
AKBA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.57%, which is quite impressive.
AKBA shows a strong growth in Revenue. In the last year, the Revenue has grown by 32.49%.
AKBA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -13.72% yearly.
EPS 1Y (TTM)69.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)32.49%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%57.01%
3.2 Future
The Earnings Per Share is expected to grow by 26.23% on average over the next years. This is a very strong growth
AKBA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.72% yearly.
EPS Next Y113.6%
EPS Next 2Y54.73%
EPS Next 3Y44.79%
EPS Next 5Y26.23%
Revenue Next Year58.44%
Revenue Next 2Y39.29%
Revenue Next 3Y28.83%
Revenue Next 5Y23.72%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AKBA. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 12.61, the valuation of AKBA can be described as correct.
97.17% of the companies in the same industry are more expensive than AKBA, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.84, AKBA is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.61 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AKBA indicates a rather cheap valuation: AKBA is cheaper than 94.91% of the companies listed in the same industry.
AKBA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AKBA is cheaper than 97.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.53 | ||
| EV/EBITDA | 15.31 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AKBA's earnings are expected to grow with 44.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y54.73%
EPS Next 3Y44.79%
5. Dividend
5.1 Amount
No dividends for AKBA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:AKBA (12/22/2025, 9:31:09 AM)
1.64
-0.02 (-1.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners47.42%
Inst Owner Change13.83%
Ins Owners3.57%
Ins Owner Change-0.3%
Market Cap435.21M
Revenue(TTM)225.07M
Net Income(TTM)-15.90M
Analysts87.27
Price Target5.51 (235.98%)
Short Float %14.36%
Short Ratio8.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)100%
Min EPS beat(2)100%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)85.7%
Min EPS beat(4)-22.55%
Max EPS beat(4)165.36%
EPS beat(8)5
Avg EPS beat(8)49.92%
EPS beat(12)8
Avg EPS beat(12)29.94%
EPS beat(16)9
Avg EPS beat(16)25.61%
Revenue beat(2)1
Avg Revenue beat(2)14.3%
Min Revenue beat(2)-1.07%
Max Revenue beat(2)29.66%
Revenue beat(4)3
Avg Revenue beat(4)18.97%
Min Revenue beat(4)-1.07%
Max Revenue beat(4)29.66%
Revenue beat(8)3
Avg Revenue beat(8)1.71%
Revenue beat(12)4
Avg Revenue beat(12)-0.75%
Revenue beat(16)8
Avg Revenue beat(16)11.83%
PT rev (1m)0%
PT rev (3m)-27.03%
EPS NQ rev (1m)-142.86%
EPS NQ rev (3m)46.43%
EPS NY rev (1m)1860%
EPS NY rev (3m)162.86%
Revenue NQ rev (1m)2%
Revenue NQ rev (3m)3.84%
Revenue NY rev (1m)-0.65%
Revenue NY rev (3m)5.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.61 | ||
| P/S | 1.93 | ||
| P/FCF | 13.53 | ||
| P/OCF | 13.43 | ||
| P/B | 10.46 | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.31 |
EPS(TTM)-0.07
EYN/A
EPS(NY)0.13
Fwd EY7.93%
FCF(TTM)0.12
FCFY7.39%
OCF(TTM)0.12
OCFY7.44%
SpS0.85
BVpS0.16
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -38.24% | ||
| ROCE | 8.73% | ||
| ROIC | 6.9% | ||
| ROICexc | 24.74% | ||
| ROICexgc | 301.13% | ||
| OM | 8.95% | ||
| PM (TTM) | N/A | ||
| GM | 82.52% | ||
| FCFM | 14.3% |
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.3 | ||
| Debt/FCF | 5.97 | ||
| Debt/EBITDA | 5.88 | ||
| Cap/Depr | 2.17% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 106.44% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | -4.39 |
F-Score4
WACC7.93%
ROIC/WACC0.87
Cap/Depr(3y)0.13%
Cap/Depr(5y)0.3%
Cap/Sales(3y)0.02%
Cap/Sales(5y)0.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y113.6%
EPS Next 2Y54.73%
EPS Next 3Y44.79%
EPS Next 5Y26.23%
Revenue 1Y (TTM)32.49%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%57.01%
Revenue Next Year58.44%
Revenue Next 2Y39.29%
Revenue Next 3Y28.83%
Revenue Next 5Y23.72%
EBIT growth 1Y162.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y142.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y142.77%
OCF growth 3YN/A
OCF growth 5YN/A
AKEBIA THERAPEUTICS INC / AKBA FAQ
What is the fundamental rating for AKBA stock?
ChartMill assigns a fundamental rating of 4 / 10 to AKBA.
Can you provide the valuation status for AKEBIA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 6 / 10 to AKEBIA THERAPEUTICS INC (AKBA). This can be considered as Fairly Valued.
How profitable is AKEBIA THERAPEUTICS INC (AKBA) stock?
AKEBIA THERAPEUTICS INC (AKBA) has a profitability rating of 4 / 10.
Can you provide the financial health for AKBA stock?
The financial health rating of AKEBIA THERAPEUTICS INC (AKBA) is 3 / 10.